4D Molecular Therapeutics, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual report, not a standalone fourth-quarter report; the filing does not provide a clear Q4-only financial result.
Business context
4D Molecular Therapeutics is a clinical-stage gene therapy company developing products based on engineered AAV vectors. Its pipeline focuses on ophthalmology, cardiology and pulmonology. At year-end, 4D-125 and 4D-110 were in eye-disease trials, and 4D-310 was in a Fabry disease trial; 4D-150 and 4D-710 were preclinical IND candidates. The company had no approved products and no product-sale revenue. Its common stock began trading on Nasdaq in December 2020.
Financial performance and liquidity
| Metric | FY2020 | FY2019 |
|---|---|---|
| Collaboration and license revenue | $13.6 million | $7.0 million |
| Research and development expense | $53.0 million | $38.7 million |
| General and administrative expense | $17.2 million | $13.9 million |
| Operating loss | $56.7 million | $50.8 million |
| Net loss | $56.7 million | $49.3 million |
| Net loss per share, basic and diluted | $8.82 | $9.59 |
| Net cash used in operating activities | $50.9 million | $36.7 million |
| Net cash used in investing activities | $1.0 million | $3.2 million |
| Net cash provided by/(used in) financing activities | $279.0 million | $(2.2) million |
Cash and cash equivalents were $276.7 million at December 31, 2020, compared with $49.7 million a year earlier. Current assets were $282.7 million and current liabilities $16.7 million. Total liabilities were $31.9 million; the filing reports no debt balance in the presented balance sheet. The company said existing cash was expected to fund planned operations for at least one year from issuance of the financial statements, while noting that additional capital would be needed for longer-term plans.
Revenue increased 95%, principally from Roche collaboration revenue, including $10.0 million in 2020 milestone payments. Roche accounted for approximately 95% of total revenue. Operating expenses rose 22%, including a 37% increase in R&D. The larger net loss reflected higher operating expenses and lower interest income; the 2019 result also included $5.1 million of acquired in-process R&D expense. No operating margin is presented; with no product sales and ongoing development costs, conventional product gross margins are not applicable.
Material changes and notable items
- The December 2020 IPO generated $204.7 million in net proceeds. Together with $72.5 million net proceeds from the Series C preferred financing, it drove the increase in cash and financing cash flow.
- All outstanding redeemable convertible preferred stock converted into common stock at the IPO; none remained outstanding at year-end.
- The company’s accumulated deficit reached $135.7 million. R&D spending increased as the company advanced its pipeline and expanded personnel and development activity.
- A $1.4 million accrual for the estimated settlement of a former employee claim was included in accrued liabilities. The company reported no material legal proceedings.
Outlook, commentary and risks
Management expected initial clinical data from 4D-125 and 4D-310 in the second half of 2021, and from 4D-110 in 2022. It expected to file INDs and begin trials for 4D-150 and 4D-710 in the second half of 2021, and to start IND-enabling studies for 4D-135 in 2021. These are forward-looking expectations, not guaranteed outcomes. No financial guidance or revenue forecast is provided.
The company expected losses and negative operating cash flows to continue, with higher R&D, administrative and manufacturing-capacity costs. Key risks include clinical or regulatory failure, gene-therapy safety and manufacturing challenges, reliance on third parties and collaborators, limited patient populations, competition, intellectual-property uncertainty, and the need for additional financing. COVID-19 could disrupt trials, research, suppliers and timelines. Management stated it was not aware of a COVID-related material impact on the 2020 financial statements, but future effects remained uncertain.
Investor verification points
- Review the audited financial statements and cash-flow runway assumptions, especially given the stated need for additional funding and continued operating losses.
- Verify the timing, enrollment, safety findings and data quality of the 4D-125, 4D-110 and 4D-310 trials, and progress toward IND filings for 4D-150 and 4D-710.
- Assess the concentration and timing of collaboration revenue, particularly Roche’s share and the contingent nature of future milestones and royalties.
- Review the $1.4 million former-employee claim accrual and any developments after the filing date.
- Track manufacturing scale-up, clinical supply, and the impact of COVID-19 or other delays on development plans and cash needs.